Medtronic unveils new procedure to treat hypertension

Mumbai: India Medtronic Private Ltd., a wholly owned subsidiary of Medtronic plc, USA launched ‘symplicity spyral renal denervation system’ (RDN) for treating high blood pressure. RDN is a minimally invasive therapy that targets nerves near the kidneys that can become overactive and cause high blood pressure. Medtronic recently announced the US Food and Drug Administration’s (US-FDA) approval of the system which is a culmination of ten years of clinical research and development, and the system has approval of the Indian regulatory authorities too.

Michael Blackwell, VP and MD, Medtronic India, said: “With the symplicity blood pressure procedure, we aim to empower healthcare professionals and offer a comprehensive approach to managing uncontrolled hypertension that supports our patient-centered approach to care. The recently announced US-FDA approval for the RDN system and an update earlier this year of the European Hypertension Society (ESH) guidelines, highlight the role of RDN as part of the hypertension care pathway.

We are excited to offer this therapy to all eligible patients in India. As leaders in cardiovascular therapies, Medtronic remains committed to providing innovative solutions that improve patients' lives.” In India, nearly 1 in 4 adults have hypertension. It is the single largest contributor to cardiovascular death; it dramatically increases risk of heart attack, stroke, heart failure, and kidney failure. Unfortunately, hypertension often goes undiagnosed as it frequently exhibits no symptoms. Raising awareness about hypertension is crucial since it is a detectable, preventable and treatable condition.